Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Tipo de documento: | Trabalho de conclusão de curso |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFRN |
Texto Completo: | https://repositorio.ufrn.br/handle/123456789/40115 |
Resumo: | Introduction: The pathophysiological abnormalities that are part of the metabolic syndrome can lead to an increase in zincuria, especially during the use of antihypertensives. Objective: To evaluate the zincuria of individuals with metabolic syndrome undergoing antihypertensive therapy. Method: We selected 34 adult and elderly individuals diagnosed with metabolic syndrome. Subjects were divided into two groups: monotherapy and combination therapy, according to the use of antihypertensives. Anthropometric measurements and biochemical analyzes were performed. Zinc intake was evaluated by means of two 24-hour reminders. The 24h urine zinc determinations were performed by atomic absorption spectrophotometry. Results: Individuals had a mean age of 47-51 years, with a predominance of female in both groups. In the monotherapy individuals group, angiotensin receptor blockers and beta-adrenergic blockers (both n = 6; 33, 30%) were predominant and in the combination therapy group combinations of angiotensin receptor blockers and diuretic (n= 7.43.80%). Zinc values in urine 24h did not differ significantly between groups (p = 1,000). Hyperzincuria was recorded in 22.22% of individuals on monotherapy and 14.29% of individuals on combination therapy. Individuals on monotherapy and combination therapy had, respectively, an average zinc intake of 6.5 (2.59) and 6.3 (3.87) mg / day, respectively, with no statistical significance between groups (p = 0.841). Statistically significant (all p <0.05) correlations were observed between dietary zinc and zincuria in the monotherapy group (Rs = 0.527, p = 0.025) and triglycerides in the combination therapy group (Rs = 0.582, p = 0.037). Conclusion: There was no alteration of the zincuria as a function of the antihypertensive therapy used, however the individuals of the monotherapy group presented a higher frequency of hyperzincuria. |
id |
UFRN_e108e67b3d832fac4c9e4f0b8311f639 |
---|---|
oai_identifier_str |
oai:https://repositorio.ufrn.br:123456789/40115 |
network_acronym_str |
UFRN |
network_name_str |
Repositório Institucional da UFRN |
repository_id_str |
|
spelling |
Silva, Isabelli Luara Costa daEvangelista, Karine Cavalcanti Maurício de SenaPedrosa, Lucia de Fátima CamposOliveira, Érika Paula Silva Freitas deEvangelista, Karine Cavalcanti Maurício de Sena2017-12-04T23:32:16Z2021-09-29T11:43:13Z2017-12-04T23:32:16Z2021-09-29T11:43:13Z2017-12-282014035333SILVA, Isabelli Luara Costa da. Excreção de zinco na urina em indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas. 2017. 39f. Trabalho de Conclusão de Curso (Graduação em Nutrição) – Curso de Nutrição, Universidade Federal do Rio Grande do Norte, Natal, 2017.https://repositorio.ufrn.br/handle/123456789/40115Introduction: The pathophysiological abnormalities that are part of the metabolic syndrome can lead to an increase in zincuria, especially during the use of antihypertensives. Objective: To evaluate the zincuria of individuals with metabolic syndrome undergoing antihypertensive therapy. Method: We selected 34 adult and elderly individuals diagnosed with metabolic syndrome. Subjects were divided into two groups: monotherapy and combination therapy, according to the use of antihypertensives. Anthropometric measurements and biochemical analyzes were performed. Zinc intake was evaluated by means of two 24-hour reminders. The 24h urine zinc determinations were performed by atomic absorption spectrophotometry. Results: Individuals had a mean age of 47-51 years, with a predominance of female in both groups. In the monotherapy individuals group, angiotensin receptor blockers and beta-adrenergic blockers (both n = 6; 33, 30%) were predominant and in the combination therapy group combinations of angiotensin receptor blockers and diuretic (n= 7.43.80%). Zinc values in urine 24h did not differ significantly between groups (p = 1,000). Hyperzincuria was recorded in 22.22% of individuals on monotherapy and 14.29% of individuals on combination therapy. Individuals on monotherapy and combination therapy had, respectively, an average zinc intake of 6.5 (2.59) and 6.3 (3.87) mg / day, respectively, with no statistical significance between groups (p = 0.841). Statistically significant (all p <0.05) correlations were observed between dietary zinc and zincuria in the monotherapy group (Rs = 0.527, p = 0.025) and triglycerides in the combination therapy group (Rs = 0.582, p = 0.037). Conclusion: There was no alteration of the zincuria as a function of the antihypertensive therapy used, however the individuals of the monotherapy group presented a higher frequency of hyperzincuria.Introdução: As anormalidades fisiopatológicas que fazem parte da síndrome metabólica podem acarretar em um aumento da zincúria como, especialmente diante do uso de anti-hipertensivos. Objetivo: Avaliar a zincúria de indivíduos com síndrome metabólica submetidos à terapia anti-hipertensiva. Método: Foram selecionados 34 indivíduos adultos e idosos diagnosticados com síndrome metabólica. Os indivíduos foram divididos em dois grupos: monoterapia e terapia combinada, conforme a utilização de anti-hipertensivos. Foram realizadas medidas antropométricas e análises bioquímicas. O zinco na dieta foi avaliado por meio de dois recordatórios de 24 horas. As determinações de zinco na urina 24h foram realizadas por espectrofotometria de absorção atômica. Resultados: Os indivíduos apresentaram média de idade entre 47 - 51 anos, com predominância do sexo feminino em ambos os grupos. No grupo de indivíduos em monoterapia houve predominância do uso de bloqueadores dos receptores de angiotensina e bloqueadores beta-adrenérgicos (ambos n= 6;33, 30%) e no grupo terapia combinada prevaleceram as combinações de bloqueadores dos receptores de angiotensina e diurético (n=7;43,80%). Os valores de zinco na urina 24h não diferiram significativamente entre os grupos (p=1,000). A hiperzincúria foi registrada em 22,22% dos indivíduos em monoterapia e 14,29% dos indivíduos em terapia combinada. Os indivíduos em monoterapia e terapia combinada apresentaram, respectivamente, um consumo médio de zinco de 6,5 (2,59) e 6,3 (3,87) mg/dia, sem significância estatística entre os grupos (p=0,841). Foram obtidas correlações estatisticamente significativas (todos p<0,05) entre a zincúria e zinco da dieta no grupo monoterapia (Rs=0,527; p=0,025) e triglicerídeos no grupo terapia combinada (Rs=0,582; p=0,037). Conclusão: Não houve alteração da zincúria em função da terapia anti-hipertensiva utilizada, entretanto os indivíduos do grupo monoterapia apresentaram maior frequência de hiperzincúria.Universidade Federal do Rio Grande do NorteUFRNBrasilNutriçãoSíndrome MetabólicaZincoZincúriaAnti-hipertensivosExcreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivasUrinary zinc excretion in subjects with metabolic syndrome using antihypertensive therapies.info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNTEXTExcreçãozincourina_2017_Trabalho de Conclusão de Curso.txtExtracted texttext/plain65510https://repositorio.ufrn.br/bitstream/123456789/40115/1/Excre%c3%a7%c3%a3ozincourina_2017_Trabalho%20de%20Conclus%c3%a3o%20de%20Curso.txtf6913f1b869b41987c914fc65b35bb29MD51ORIGINALExcreçãozincourina_2017_Trabalho de Conclusão de CursoTexto Completoapplication/octet-stream1159346https://repositorio.ufrn.br/bitstream/123456789/40115/2/Excre%c3%a7%c3%a3ozincourina_2017_Trabalho%20de%20Conclus%c3%a3o%20de%20Cursobbdca4369576fa91b2a2411553660701MD52LICENSElicense.txttext/plain756https://repositorio.ufrn.br/bitstream/123456789/40115/3/license.txta80a9cda2756d355b388cc443c3d8a43MD53CC-LICENSElicense_urlapplication/octet-stream46https://repositorio.ufrn.br/bitstream/123456789/40115/4/license_url6f1da3ff281999354d4abd56d1551468MD54license_textapplication/octet-stream0https://repositorio.ufrn.br/bitstream/123456789/40115/5/license_textd41d8cd98f00b204e9800998ecf8427eMD55license_rdfapplication/octet-stream0https://repositorio.ufrn.br/bitstream/123456789/40115/6/license_rdfd41d8cd98f00b204e9800998ecf8427eMD56123456789/401152021-09-29 08:43:13.531oai:https://repositorio.ufrn.br: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ório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2021-09-29T11:43:13Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false |
dc.title.pr_BR.fl_str_mv |
Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas |
dc.title.alternative.pr_BR.fl_str_mv |
Urinary zinc excretion in subjects with metabolic syndrome using antihypertensive therapies. |
title |
Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas |
spellingShingle |
Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas Silva, Isabelli Luara Costa da Síndrome Metabólica Zinco Zincúria Anti-hipertensivos |
title_short |
Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas |
title_full |
Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas |
title_fullStr |
Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas |
title_full_unstemmed |
Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas |
title_sort |
Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas |
author |
Silva, Isabelli Luara Costa da |
author_facet |
Silva, Isabelli Luara Costa da |
author_role |
author |
dc.contributor.referees1.none.fl_str_mv |
Evangelista, Karine Cavalcanti Maurício de Sena |
dc.contributor.referees2.none.fl_str_mv |
Pedrosa, Lucia de Fátima Campos |
dc.contributor.referees3.none.fl_str_mv |
Oliveira, Érika Paula Silva Freitas de |
dc.contributor.author.fl_str_mv |
Silva, Isabelli Luara Costa da |
dc.contributor.advisor1.fl_str_mv |
Evangelista, Karine Cavalcanti Maurício de Sena |
contributor_str_mv |
Evangelista, Karine Cavalcanti Maurício de Sena |
dc.subject.pr_BR.fl_str_mv |
Síndrome Metabólica Zinco Zincúria Anti-hipertensivos |
topic |
Síndrome Metabólica Zinco Zincúria Anti-hipertensivos |
description |
Introduction: The pathophysiological abnormalities that are part of the metabolic syndrome can lead to an increase in zincuria, especially during the use of antihypertensives. Objective: To evaluate the zincuria of individuals with metabolic syndrome undergoing antihypertensive therapy. Method: We selected 34 adult and elderly individuals diagnosed with metabolic syndrome. Subjects were divided into two groups: monotherapy and combination therapy, according to the use of antihypertensives. Anthropometric measurements and biochemical analyzes were performed. Zinc intake was evaluated by means of two 24-hour reminders. The 24h urine zinc determinations were performed by atomic absorption spectrophotometry. Results: Individuals had a mean age of 47-51 years, with a predominance of female in both groups. In the monotherapy individuals group, angiotensin receptor blockers and beta-adrenergic blockers (both n = 6; 33, 30%) were predominant and in the combination therapy group combinations of angiotensin receptor blockers and diuretic (n= 7.43.80%). Zinc values in urine 24h did not differ significantly between groups (p = 1,000). Hyperzincuria was recorded in 22.22% of individuals on monotherapy and 14.29% of individuals on combination therapy. Individuals on monotherapy and combination therapy had, respectively, an average zinc intake of 6.5 (2.59) and 6.3 (3.87) mg / day, respectively, with no statistical significance between groups (p = 0.841). Statistically significant (all p <0.05) correlations were observed between dietary zinc and zincuria in the monotherapy group (Rs = 0.527, p = 0.025) and triglycerides in the combination therapy group (Rs = 0.582, p = 0.037). Conclusion: There was no alteration of the zincuria as a function of the antihypertensive therapy used, however the individuals of the monotherapy group presented a higher frequency of hyperzincuria. |
publishDate |
2017 |
dc.date.accessioned.fl_str_mv |
2017-12-04T23:32:16Z 2021-09-29T11:43:13Z |
dc.date.available.fl_str_mv |
2017-12-04T23:32:16Z 2021-09-29T11:43:13Z |
dc.date.issued.fl_str_mv |
2017-12-28 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
format |
bachelorThesis |
status_str |
publishedVersion |
dc.identifier.pr_BR.fl_str_mv |
2014035333 |
dc.identifier.citation.fl_str_mv |
SILVA, Isabelli Luara Costa da. Excreção de zinco na urina em indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas. 2017. 39f. Trabalho de Conclusão de Curso (Graduação em Nutrição) – Curso de Nutrição, Universidade Federal do Rio Grande do Norte, Natal, 2017. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufrn.br/handle/123456789/40115 |
identifier_str_mv |
2014035333 SILVA, Isabelli Luara Costa da. Excreção de zinco na urina em indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas. 2017. 39f. Trabalho de Conclusão de Curso (Graduação em Nutrição) – Curso de Nutrição, Universidade Federal do Rio Grande do Norte, Natal, 2017. |
url |
https://repositorio.ufrn.br/handle/123456789/40115 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Universidade Federal do Rio Grande do Norte |
dc.publisher.initials.fl_str_mv |
UFRN |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Nutrição |
publisher.none.fl_str_mv |
Universidade Federal do Rio Grande do Norte |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRN instname:Universidade Federal do Rio Grande do Norte (UFRN) instacron:UFRN |
instname_str |
Universidade Federal do Rio Grande do Norte (UFRN) |
instacron_str |
UFRN |
institution |
UFRN |
reponame_str |
Repositório Institucional da UFRN |
collection |
Repositório Institucional da UFRN |
bitstream.url.fl_str_mv |
https://repositorio.ufrn.br/bitstream/123456789/40115/1/Excre%c3%a7%c3%a3ozincourina_2017_Trabalho%20de%20Conclus%c3%a3o%20de%20Curso.txt https://repositorio.ufrn.br/bitstream/123456789/40115/2/Excre%c3%a7%c3%a3ozincourina_2017_Trabalho%20de%20Conclus%c3%a3o%20de%20Curso https://repositorio.ufrn.br/bitstream/123456789/40115/3/license.txt https://repositorio.ufrn.br/bitstream/123456789/40115/4/license_url https://repositorio.ufrn.br/bitstream/123456789/40115/5/license_text https://repositorio.ufrn.br/bitstream/123456789/40115/6/license_rdf |
bitstream.checksum.fl_str_mv |
f6913f1b869b41987c914fc65b35bb29 bbdca4369576fa91b2a2411553660701 a80a9cda2756d355b388cc443c3d8a43 6f1da3ff281999354d4abd56d1551468 d41d8cd98f00b204e9800998ecf8427e d41d8cd98f00b204e9800998ecf8427e |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN) |
repository.mail.fl_str_mv |
|
_version_ |
1802117674993451008 |